Impax cuts nearly 50 employees to save money

Impax Laboratories ($IPXL), which has struggled for several years to get its Parkinson's drug Rytary to market, is moving away from early-stage research and has cut its R&D staff by 42 jobs, a 25% reduction to save money. The cut of a total of 49 positions at the company is expected to save $8 million a year. From here on out, Impax's branded R&D efforts will focus on products in Phase II and above, the company said in a statement today. Ongoing FDA concerns about Impax' manufacturing has delayed approval of Rytary for some time. Story | More

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.